Sunnyvale, CA – January 6, 2016 — Elixir Medical Corporation, a privately held medical company, is scheduled to participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Motasim Sirhan, Chief Executive Officer, will make a presentation about Elixir Medical on Tuesday, January 12, 2016 at 4:30 p.m. PST (7:30 p.m. EST) in the Elizabethan C Room at the Westin St. Francis.
About Elixir Medical
Elixir Medical Corporation develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide physicians with innovative treatment solutions for their patients. The company was founded in 2005 and is based in Sunnyvale, California.
Elixir’s initial area of focus is coronary vascular intervention, with a broad portfolio of products leveraging Elixir’s unique pharmaceutical, drug release, stent platforms, and scaffold technologies:
- DESolve®: CE Mark-approved fully bioresorbable drug eluting scaffold system
- DESyne BD®: CE Mark-approved degradable coating drug eluting stent system
- DESyne®: CE Mark-approved durable polymer coating drug eluting stent system
Elixir is also developing bioresorbable scaffolds for peripheral vascular indications. The peripheral programs are currently in the pre-clinical phase.
For more information on the company and its products, please visit www.elixirmedical.com.